Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

Figure 5

Effects of RDEA119 plus rapamycin combination on downstream signalling. Tumour lysates obtained 4 h after the final dose of RDEA119 or/and 48 h after the final dose of rapamycin in the chronic dosing groups of animals were analyzed by western blot using the indicated antibodies. Representative blots showed the effect of combined inhibition of MEK and mTOR on downstream signalling.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us